A Randomized, Double-blind, Comparative Study of Abiraterone Acetate Plus Low-dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Subjects With High-Risk, Metastatic Hormone-naive Prostate Cancer (mHNPC)

Trial Profile

A Randomized, Double-blind, Comparative Study of Abiraterone Acetate Plus Low-dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Subjects With High-Risk, Metastatic Hormone-naive Prostate Cancer (mHNPC)

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 05 Jun 2018

At a glance

  • Drugs Abiraterone acetate (Primary) ; LHRH receptor agonists; Prednisone
  • Indications Adenocarcinoma; Prostate cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms LATITUDE
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 05 Jun 2018 Results assessing subsequent therapies after abiraterone acetate + prednisone, presented at the 54th Annual Meeting of the American Society of Clinical Oncology
    • 05 Jun 2018 Results assessing long term preplanned efficacy and safety analysis presented at the 54th Annual Meeting of the American Society of Clinical Oncology
    • 23 May 2018 Results of post hoc analysis assessing EQ-5D-5L visual analog scale (VAS) time to deterioration, assessing clinically relevant minimally important differences (MIDs), in the LATITUDE study of patients with mHSPC, were presented at the 23rd Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top